RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > 2020 > 7 > Recon: US to pay $2.1B for Sanofi, GSK COVID-19 vaccines; AbbVie, Gilead report Q2 results

Recon: US to pay $2.1B for Sanofi, GSK COVID-19 vaccines; AbbVie, Gilead report Q2 results

Posted 31 July 2020 | By Michael Mezher 

Recon: US to pay $2.1B for Sanofi, GSK COVID-19 vaccines; AbbVie, Gilead report Q2 results

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.
In Focus: US
  • US to pay $2.1B to Sanofi, GSK, in COVID-19 vaccine deal (Reuters) (Politico) (NYTimes) (Press)
  • Trump planning for US rollout of coronavirus vaccine falling short, officials warn (Reuters)
  • Large US COVID-19 vaccine trials will exclude pregnant women for now (Reuters)
  • Merck plans large trials of antiviral COVID-19 drug in September (Reuters)
  • China-backed hackers 'targeted COVID-19 vaccine firm Moderna' (Reuters)
  • Moderna board member resigns to avoid conflict of interest during vaccine trial (CNBC) (STAT)
  • NIH investing $248.7 million in seven companies to scale up COVID-19 testing (Reuters)
  • Ginkgo, Mammoth among winners of NIH’s ‘Shark Tank’ for Covid-19 tests (STAT)
  • Gilead Raises 2020 Profit Outlook on Remdesivir Demand (WSJ) (CNBC)
  • AbbVie's Humira powers profit beat as COVID-19 weighs on Botox sales (Reuters) (Press)
In Focus: International
  • Impact of coronavirus will be felt for decades to come, WHO says (Reuters)
  • Pfizer, BioNTech to supply 120 million doses of coronavirus vaccine to Japan (Reuters) (Press)
  • Gilead hopes to meet global remdesivir demand by October (FT)
  • Seasonal flu reports hit record lows amid global social distancing (NBC)
  • Takeda Announces FY2020 Q1 Results (Press)
  • Global regulatory workshop on COVID-19 real-world evidence and observational studies (EMA)
  • Global regulatory workshop on COVID-19 therapeutics #2: agreement on acceptable endpoints for clinical trials (EMA)
Coronavirus Pandemic
  • AstraZeneca signals it won't wait for US data to seek clearance of coronavirus vaccine (BioPharmaDive)
  • CytoDyn CEO claims Covid-19 drug success while describing data suggesting study failure (STAT)
  • House Democrats find Trump officials overpaid for ventilators by as much as $500 million (The Hill)
  • COVID-19 Hospital Data System That Bypasses CDC Plagued By Delays, Inaccuracies (NPR)
  • Trump testing czar says 56 percent of COVID-19 results coming back within three days (The Hill)
  • Trump urges recovered COVID-19 patients to donate plasma (The Hill)
  • Early coronavirus drug trials tested vaccines mostly on White people; next phase aims for diversity (CNBC)
  • Children May Carry Coronavirus at High Levels, Study Finds (NYTimes)
  • Aboard the Diamond Princess, a Case Study in Aerosol Transmission (NYTimes)
  • Coronavirus (COVID-19) Update: Daily Roundup July 30, 2020 (FDA)
  • Brazil Issues Guidance For Clinical Trials Conducted During Pandemic (Pink Sheet)
Pharma & Biotech
  • Trump’s ‘radical’, ‘horrible’ executive orders on drug pricing earn a C-suite backlash this week — with one threat to do more overseas (Endpoints)
  • Roche's Tecentriq triplet nabs melanoma OK, but BMS' Opdivo-Yervoy still reigns supreme (Fierce) (Endpoints)
  • BioNTech and Regeneron launch new melanoma collab; Harbour BioMed finds incubation partner (Endpoints)
  • AlloVir rides IPO boom on first market day, soars after bagging $276 million (Endpoints)
  • Tetraphase deal done, La Jolla Pharmaceutical taps Larry Edwards as CEO; Longtime Eli Lilly exec Michael Overdorf heads to Annexon as CBO (Endpoints)
  • FDA expands Stelara indication to cover paediatric plaque psoriasis (Pharmafile)
  • NICE backs Bavencio combo for kidney cancer (PharmaTimes)
  • EU regulators approve Novartis' breast cancer combo (PharmaTimes)
  • EU Pilot Facilitates Multilingual Packaging To Improve Medicines Availability (Pink Sheet)
  • Eargo raises $71M for its 'invisible,' direct-to-consumer hearing aid (Fierce)
  • Teleflex reports rapid rebound in UroLift sales, driving Q2 beat (MedtechDive)
  • Hologic blows away earnings expectations on COVID-19 testing surge (MedtechDive)
  • Baxter takes $180M revenue hit in thick of COVID-19 (MedtechDive)
  • Medtechs’ View Of UK Brexit Deal: More Certainty, But Still No Detail (MedtechInsight)
Government & Regulatory
  • Sanofi And GSK Face DOJ Probes Over Zantac Cancer Risk (Law360)
  • Biogen Can't Block Mylan MS Drug Launch During IP Appeal (Law360) (Endpoints)
  • Juul Seeks FDA Approval To Market E-Cigarettes (Law360)
  • Humira Buyers Take AbbVie Antitrust Challenge To 7th Circ. (Law360)
  • Justices Told Horizon's IP Loss 'Casts A Pall' On 32K Patents (Law360)
Regulatory Recon is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe.
A story's inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.


© 2022 Regulatory Affairs Professionals Society.

Tags: US, worldwide

Regulatory Focus newsletters

All the biggest regulatory news and happenings.